Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Apr;22(4):225–231. doi: 10.1101/lm.036699.114

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Bowers et al.; Published by Cold Spring Harbor Laboratory Press

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first 12 months after the full-issue publication date (see http://learnmem.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Figure 1. — RGFP963 and RGFP966 compound properties in vitro and in vivo. (A) RGFP966 exhibits specific inhibition of HDAC3, while RGFP963 broadly inhibits HDAC1, HDAC2, and HDAC3 in vitro. (B) Chemical structures of RGFP963 and RGFP966. (C,D) Of note, 10 mg/kg RGFP966 and RGFP963 are detected 0.25, 1, and 2 h post-IP injection (n = 3/group). Of note, 10 mg/kg RGFP966 is capable of inhibiting HDAC3, while minimally inhibiting HDAC1 and HDAC2, at the various time points assessed. Of note, 10 mg/kg RGFP963 is capable of inhibiting HDAC1, HDAC2, and HDAC3 at the various time points assessed. (E–P″) Vehicle, 10 mg/kg RGFP966, and 10 mg/kg RGFP963 were administered IP (n = 2/group). Subjects were perfused 1 h after drug administration and then tissue was processed for immunocytochemistry to determine an effect of drug on global H3 and H4 acetylation levels in the basolateral amygdala (BLA) and dentate gyrus (DG) region of the hippocampus. (E–E″) Photomicrographs showing colocalization of DAPI (E) and global acetyl H3 (E′) in the BLA with vehicle administration (E″ merged). (F–F″) Photomicrographs showing colocalization of DAPI (F) and global acetyl H3 (F′) in the BLA with 10 mg/kg RGFP966 administration (F″ merged). (G–G″) Photomicrographs showing colocalization of DAPI (G) and global acetyl H3 (G′) in the BLA with 10 mg/kg RGFP963 administration (G″ merged). (H–H″) Photomicrographs showing colocalization of DAPI (H) and global acetyl H3 (H′) in the DG with vehicle administration (H″ merged). (I–I″) Photomicrographs showing colocalization of DAPI (I) and global acetyl H3 (I′) in the DG with 10 mg/kg RGFP966 administration (I″ merged). (J–J″) Photomicrographs showing colocalization of DAPI (J) and global acetyl H3 (J′) in the DG with 10 mg/kg RGFP963 administration (J″ merged). (K–K″) Photomicrographs showing colocalization of DAPI (K) and global acetyl H4 (K′) in the BLA with vehicle administration (K″ merged). (L–L″) Photomicrographs showing colocalization of DAPI (L) and global acetyl H4 (L′) in the BLA with 10 mg/kg RGFP966 administration (L″ merged). (M–M″) Photomicrographs showing colocalization of DAPI (M) and global acetyl H4 (M′) in the BLA with 10 mg/kg RGFP963 administration (M″ merged). (N–N″) Photomicrographs showing colocalization of DAPI (N) and global acetyl H4 (N′) in the DG with vehicle administration (N″ merged). (O–O″) Photomicrographs showing colocalization of DAPI (O) and global acetyl H4 (O′) in the DG with 10 mg/kg RGFP966 administration (O″ merged). (P–P″) Photomicrographs showing colocalization of DAPI (P) and global acetyl H4 (P′) in the DG with 10 mg/kg RGFP963 administration (P″ merged).